Titusville: Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved CAPLYTA ...

The number of people suffering from depression or bipolar disorders in Korea has surged, with cases of each of the conditions ...

The number of South Koreans diagnosed with depression and bipolar disorder each increased nearly 1.5-fold over the past six ...

The J&J antipsychotic drug Caplyta won FDA approval for depression, a broader indication that could help the medicine become ...

In short, actively seek out something to smile about—even if the smile feels forced. According to Allyson Pimentel of the ...

The expanded indication for the oral atypical antipsychotic now includes adjunctive use with antidepressants in adults with major depressive disorder.

Why hadn’t I been able to save my son? What biological mechanisms made him so relentlessly ill? Could more effective ...

Lumateperone is approved as an adjunctive treatment for MDD, expanding its indications beyond schizophrenia and bipolar ...

Caplyta, the crown jewel of Johnson & Johnson's $14.6 billion buyout of Intra-Cellular Therapies, won the FDA’s blessing to ...

The number of people in South Korea suffering from depression and bipolar disorder has increased by more than 40% over the past six years. In ...

Johnson & Johnson (JNJ) stock is in focus as the FDA further expands the labeling for its antipsychotic to treat adults with ...